Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets

The need for optimal treatment of the active forms of multiple sclerosis (MS), especially highly active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice of a highly effective disease-modifying drug for MS (DMDMS), but also conditions for the timely and safe switching from other DMDMS. A group of expert neurologists from various clinics in Russia presents a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets, which has been registered in Russia in March 2020. The paper discusses indications for changing therapy and gives indications, contraindications, and conditions for initiating cladribine therapy. It details the procedure and results of the expert consensus, on the basis of which the recommendations have been developed to switch to cladribine tablets from each of the DMDMS registered in Russia for the treatment of MS.

1. Grand’Maison F, Yeung M, Morrow SA, et al. Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Curr Med Res Opin. 2018 Aug;34(8):1419-30. doi: 10.1080/03007995.2018.1458023. Epub 2018 Apr 18.

2. Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 2019 May;30:215-24. doi: 10.1016/j.msard.2019.01.039. Epub 2019 Jan 24.

3. Coyle PK. Switching therapies in multiple sclerosis. CNS Drugs. 2013 Apr;27(4):239-47. doi: 10.1007/s40263-013-0042-5

4. Ohlmeier C, Gothe H, Haas J, et al. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLoS One. 2020 May 1;15(5):e0231846. doi: 10.1371/journal.pone.0231846. eCollection 2020.

5. Freedman MS, Devonshire V, Duquette P, et al. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Canad J Neurol Sci. 2020;47:437-55. doi: 10.1017/cjn.2020.66

6. Boyko AN, Boyko OV, Gusev YeI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem (a review). Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2014;114(10):77-91 (In Russ.).

7. Boiko AN, Gusev EI. Contemporary Algorithms for the Diagnosis and Treatment of Multiple Sclerosis Based on Individual Assessment of Patients’ Status. Neurosci Behav Physiol. 2018;48(7):870-82. doi: 10.1007/s11055-018-0642-0

8. Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017 Oct;14(4):874-87. doi: 10.1007/s13311-017-0573-4.

9. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26. doi: 10.1056/NEJMoa0902533. Epub 2010 Jan 20.

10. Giovannoni G, Sorensen PS, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scleros J. 2018;24(12):1594-604. doi: 10.1177/1352458517727603

11. Giovannoni G, Sorensen PS, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scleros J. 2019;25(6):819- 27. doi: 10.1177/1352458518771875

12. Celius EG, Berg-Hansen P. Cladribine as treatment of multiple sclerosis, real world experience. Mult Scleros J. 2019;25:527-8.

13. Instructions for medical use of the drug Mavenclad (cladribine). Available from: https://medi.ru/instrukciya/mavenklad_16806/ (In Russ.).

14. Bakhtiyarova KZ, Boyko AN, Vlasov YaV, et al. Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):93-9. doi: 10.14412/2074-2711-2020-3-93-99 (In Russ.).

15. KKNMS Guidelines. 3rd ed. July 2018. Available from: https://www.kompetenznetz-multiplesklerose.de/wp-content/uploads/2018/11/KKNMS_Qualit%C3%A4tshandbuch-MSNMOSD_2018_webfrei.pdf (accessed 20 April 2020).

16. Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019 Apr;29:157-67. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.

17. Sorensen PS, Heick A, Petersen T, et al. Danish experience with cladribine tablets in the treatment of relapsing multiple sclerosis: A nationwide study. Mult Scleros J. 2019;25:165.

18. Vermersch P, Martinelli V, Pfleger C, et al. Benefit-risk Assessment of Cladribine Using Multicriteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis. Clin Ther. 2019 Feb;41(2):249-60.e18. doi: 10.1016/j.clinthera.2018.12.015